T. Spelman Et Al. , "Comparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remetting multiple sclerosis therapy: propensity score matching analysis from the MSBase registry," 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis , Berlin, Germany, pp.31, 2018
Spelman, T. Et Al. 2018. Comparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remetting multiple sclerosis therapy: propensity score matching analysis from the MSBase registry. 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis , (Berlin, Germany), 31.
Spelman, T., Havrdova, E., Horakova, D., Izquierdo, G., Kalincik, T., Lugaresi, A., ... Onofrj, M.(2018). Comparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remetting multiple sclerosis therapy: propensity score matching analysis from the MSBase registry . 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (pp.31). Berlin, Germany
Spelman, Tim Et Al. "Comparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remetting multiple sclerosis therapy: propensity score matching analysis from the MSBase registry," 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Berlin, Germany, 2018
Spelman, Tim Et Al. "Comparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remetting multiple sclerosis therapy: propensity score matching analysis from the MSBase registry." 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis , Berlin, Germany, pp.31, 2018
Spelman, T. Et Al. (2018) . "Comparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remetting multiple sclerosis therapy: propensity score matching analysis from the MSBase registry." 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis , Berlin, Germany, p.31.
@conferencepaper{conferencepaper, author={Tim Spelman Et Al. }, title={Comparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remetting multiple sclerosis therapy: propensity score matching analysis from the MSBase registry}, congress name={34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis}, city={Berlin}, country={Germany}, year={2018}, pages={31} }